drugset / Trial / NCT01994031

Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments

NCT01994031

Phase 4 Unknown 36 enrolled Nanjing Luye Sike Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD)of paclitaxel liposome injection and to compare the pharmacokinetic characters between paclitaxel liposome injection and paclitaxel injection and to value the effectiveness for cancer treatment.

Timeline

Start
2014-08
Primary completion
2015-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 135 mg/m2
Subject Paclitaxel Small molecule 175 mg/m2
Subject Paclitaxel Small molecule 210 mg/m2
Subject Paclitaxel Small molecule 250 mg/m2
Subject Paclitaxel Small molecule 300 mg/m2

Indications